Skip to main navigationSkip to main content
The University of Southampton
We're launching a new website soon and would love your feedback. See the new design
Growth Hormone 2004 Project

GH-2004 - Fighting Growth Hormone misuse in Sport 

It is widely believed that athletes have been misusing growth hormone (GH) for its anabolic and lipolytic effects since the early 1980s. The use of GH was prohibited by the International Olympic Committee (IOC) in 1989 and GH appears on the current World Anti-Doping Agency (WADA) list of prohibited substances. The need for an effective test to detect GH was recognised by the International Olympic Committee (IOC) in 1991.

In 1996 GH-2000, a multi-national research group, involving Academic Institutions in Sweden, Denmark, Italy and UK and the two major manufacturers of recombinant human growth hormone (GH) NovoNordisk and Pharmacia, funded by the European Union (EU) and the International Olympic Committee (IOC) set out to develop a reliable methodology to detect GH misuse in professional sport.

In their final report in January 1999, the group proposed a methodology based on the measurement of two biomarkers that would detect GH misuse up to 28 days after the last injection.

Following this the IOC and the newly-created World Anti-Doping Agency (WADA) requested further validation of this methodology in order to be able to identify "beyond reasonable doubt" GH dopers with minimal risk of false accusation. After obtaining funding from the United States Anti-Doping Agency (USADA) in December 2002, the GH-2004 project was set up at the University of Southampton with the aim of completing the validation of the GH-2000 'biomarker' methodology.

King's College London Drug Control Centre logo
UKAD logo
Privacy Settings